Table 2.
Univariate analysis for the 5-year and 10-year DSS in patients (n = 81) with head and neck AdCC
| Parameter | n | 5-year | p | 10-year | p | ||
|---|---|---|---|---|---|---|---|
| DSS (95% CI) | HR (95% CI) | DSS (95% CI) | HR (95% CI) | ||||
| Age | |||||||
| ≤ 50 years | 38 | 94.74 (80.56–98.66) | 3.63 (0.77–17.14) | 0.080 | 78.95 (62.29–88.87) | 2.43 (1.06–5.56) | 0.029 |
| > 50 years | 43 | 81.40 (66.22–90.23) | 55.81 (39.85–69.10) | ||||
| Sex | |||||||
| Male | 37 | 89.19 (73.71–95.80) | 1.22 (0.34–4.34) | 0.752 | 56.76 (39.43–70.84) | 0.54 (0.25–1.17) | 0.114 |
| Female | 44 | 86.36 (72.14–93.63) | 75.00 (59.42–85.30) | ||||
| Primary site | |||||||
| Major SG | 43 | 86.05 (71.55–93.48) | 0.75 (0.21–2.66) | 0.659 | 67.44 (51.31–79.25) | 1.07 (0.50–2.29) | 0.844 |
| Minor SG/other sites | 38 | 89.47 (74.34–95.91) | 65.79 (48.48–78.49) | ||||
| Tumor size (T) | |||||||
| T1/T2 | 38 | 94.74 (80.56–98.66) | 3.77 (0.80–17.76) | 0.071 | 86.84 (71.23–94.30) | 4.81 (1.81–12.72) | < 0.001 |
| T3/T4 | 43 | 81.40 (66.22–90.23) | 48.84 (33.34–62.65) | ||||
| Lymph node metastasis (N) | |||||||
| N0 | 69 | 85.51 (74.74–91.93) | a | 0.172 | 68.12 (55.73–77.71) | 1.23 (0.46–3.25) | 0.672 |
| N1/N2/N3 | 12 | a | 58.33 (27.01–80.09) | ||||
| Distant metastasis (M) | |||||||
| M0 | 67 | 97.01 (88.59–99.24) | 27.11 (5.72–128.52) | < 0.001 | 80.60 (68.94–88.24) | 16.15 (7.19–36.24) | < 0.001 |
| M1 | 14 | 42.86 (17.73–66.04) | 7.14 (0.45–27.52) | ||||
| Clinical stage | |||||||
| I/II | 32 | 96.88 (79.82–99.55) | 6.27 (0.79–49.57) | 0.045 | 96.88 (79.82–99.55) | 22.83 (3.09–168.50) | < 0.001 |
| III/IV | 49 | 81.63 (67.67–89.99) | 46.94 (32.59–60.04) | ||||
| Histopathological pattern | |||||||
| Tubular/cribriform | 62 | 93.55 (83.72–97.53) | 5.35 (1.50–18.98) | 0.003 | 77.42 (64.87–85.95) | 3.94 (1.84–8.42) | < 0.001 |
| Solid | 19 | 68.42 (42.79–84.39) | 31.58 (12.91–52.25) | ||||
| Perineural invasion | |||||||
| Absent | 29 | 96.55 (77.9–99.51) | 5.29 (0.67–41.79) | 0.076 | 86.21 (67.31–94.59) | 3.84 (1.32–11.13) | 0.007 |
| Present | 52 | 82.69 (69.38–90.59) | 55.77 (41.32–67.99) | ||||
| Surgical margins | |||||||
| Negative | 44 | 95.45 (83.02–98.84) | 5.26 (1.11–24.78) | 0.018 | 95.45 (83.02–98.84) | 22.45 (5.29–95.24) | < 0.001 |
| Positive | 37 | 78.38 (61.39–88.55) | 32.43 (18.23–47.47) | ||||
| Treatment | |||||||
| Surgery | 12 | 91.67 (53.90–98.78) | 1.83 (0.65–5.17) | 0.403 | 83.33 (48.17–95.55) | 4.20 (1.91–9.25) | < 0.001 |
| Surgery + RT | 36 | 91.67 (76.35–97.23) | 88.89 (73.05–95.68) | ||||
| Surgery + RT + ChT | 26 | 80.77 (59.81–91.51) | 34.62 (17.46–52.48) | ||||
Seven cases were not included in analysis of association between DSS and treatment: two patients submitted to surgery and ChT; four patients submitted to RT and ChT; and one submitted to ChT
Bold values indicate statistically significant results
DSS disease-specific survival, CI confidence interval, HR hazard ratio, SG salivary gland, RT radiotherapy, ChT chemotherapy
aIt was not possible to determine